Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Pia Burman, Britt Edén-Engström, Bertil Ekman, F Anders Karlsson, Erik Schwarcz, Jeanette Wahlberg

Research output: Contribution to journalArticlepeer-review

Abstract

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.
Original languageEnglish
Pages (from-to)17-24
JournalEuropean Journal of Endocrinology
Volume174
Issue number1
DOIs
Publication statusPublished - 2016

Subject classification (UKÄ)

  • Endocrinology and Diabetes

Fingerprint

Dive into the research topics of 'Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.'. Together they form a unique fingerprint.

Cite this